Exelixis logo

Clinical trials & pipeline

We are advancing a diverse and promising portfolio of clinically differentiated compounds through internal development and strategic external partnerships.

Molecules
Tumor Types
Key Trials
Phases of Development
Phase 3
STELLAR-303
Colorectal Cancer
Zanzalintinib + atezolizumab vs. regorafenib
Phase 3
STELLAR-304
Non-Clear Cell Renal Cell Carcinoma
Zanzalintinib + nivolumab vs. sunitinib
Phase 2/3
STELLAR-311
Neuroendocrine Tumors
Zanzalintinib vs. everolimus
Phase 3

LITESPARK-0331

Renal Cell Carcinoma
Zanzalintinib + belzutifan vs. cabozantinib
Phase 3

LITESPARK-0342

Renal Cell Carcinoma
Zanzalintinib + belzutifan vs. belzutifan + placebo
Phase 2
STELLAR-201
Meningioma
Zanzalintinib
Phase 1b/2
STELLAR-001
Multiple Solid Tumors
Zanzalintinib or zanzalintinib + atezolizumab
Phase 1b/2
STELLAR-002
Multiple Solid Tumors
Zanzalintinib or zanzalintinib + nivolumab or zanzalintinib + nivolumab + ipilimumab or zanzalintinib + nivolumab + relatlimab
Phase 1b/2

KEYMAKER-U032

Renal Cell Carcinoma
Zanzalintinib + belzutifan
Phase 1
Unnamed
Multiple Solid Tumors
XL309 or XL309 + olaparib
Phase 1
Unnamed
Multiple Solid Tumors
XB010 or XB010 + pembrolizumab
Phase 1
Unnamed
Multiple Solid Tumors
XB628
Phase 1
Unnamed
Multiple Solid Tumors
XB371
Phase 1

Sairopa3

Multiple Solid Tumors
ADU-1805 or ADU-1805 + pembrolizumab

1 Merck is sponsoring the study, and Exelixis is supplying the study drugs, zanzalintinib and cabozantinib
2 Merck is sponsoring the study, and Exelixis is supplying the study drug, zanzalintinib
3 Sairopa B.V. (Sairopa) and Exelixis have an exclusive clinical development and option agreement providing Exelixis the right to acquire ADU-1805

Disclaimer: The compounds presented are investigational or are being investigated for uses that have not been approved by the U.S. Food and Drug Administration. The safety and efficacy of these investigational compounds and/or investigational uses have not been established. This information is presented only for purposes of providing a general overview of clinical trials and should not be construed as a recommendation for use of any product for unapproved uses.

Asset/Program
  • Discovery/Preclinical Disc/Pre
  • IND IND
  • Phase 1 Phase 1
  • Phase 1b/2 Phase 1b/2
  • Phase 2 Phase 2
  • Pivotal Pivotal
Zanzalintinib
Pivotal, Phase 2 and Phase 1b/2

STELLAR-303 (CRC)

STELLAR-303 (CRC)

STELLAR-304 (nccRCC)

STELLAR-304 (nccRCC)

STELLAR-311 (NET)

STELLAR-311 (NET)

LITESPARK-033 (RCC) – in partnership with Merck1

LITESPARK-033 (RCC) – in partnership with Merck1

LITESPARK-034 (RCC) – in partnership with Merck2

LITESPARK-034 (RCC) – in partnership with Merck2

STELLAR-201 (Meningioma)

STELLAR-201 (Meningioma)

STELLAR-001 (Solid tumors)

STELLAR-001 (Solid tumors)

STELLAR-002 (Solid tumors)

STELLAR-002 (Solid tumors)

KEYMAKER-U03 (RCC) – in partnership with Merck2

KEYMAKER-U03 (RCC) – in partnership with Merck2

XL092; Next-generation TKI targeting MET/VEGFR/AXL/MER

XL092; Next-generation TKI targeting MET/VEGFR/AXL/MER

Pivotal

STELLAR-303 (CRC)

STELLAR-303 (CRC)
Pivotal

STELLAR-304 (nccRCC)

STELLAR-304 (nccRCC)
Pivotal

STELLAR-311 (NET)

STELLAR-311 (NET)
Pivotal

LITESPARK-033 (RCC) – in partnership with Merck1

LITESPARK-033 (RCC) – in partnership with Merck1
Pivotal

LITESPARK-034 (RCC) – in partnership with Merck2

LITESPARK-034 (RCC) – in partnership with Merck2
Phase 2

STELLAR-201 (Meningioma)

STELLAR-201 (Meningioma)
Phase 1b/2

STELLAR-001 (Solid tumors)

STELLAR-001 (Solid tumors)
Phase 1b/2

STELLAR-002 (Solid tumors)

STELLAR-002 (Solid tumors)
Phase 1b/2

KEYMAKER-U03 (RCC) – in partnership with Merck2

KEYMAKER-U03 (RCC) – in partnership with Merck2
XL309
Phase 1

Phase 1 (Solid tumors)

Phase 1 (Solid tumors)

USP1 inhibitor

USP1 inhibitor

Phase 1

Phase 1 (Solid tumors)

Phase 1 (Solid tumors)
XB010
Phase 1

Phase 1 (Solid tumors)

Phase 1 (Solid tumors)

Next-generation 5T4-MMAE ADC

Next-generation 5T4-MMAE ADC

Phase 1

Phase 1 (Solid tumors)

Phase 1 (Solid tumors)
XB628
Phase 1

Phase 1 (Solid tumors)

Phase 1 (Solid tumors)

PD-L1 + NKG2A bispecific antibody

PD-L1 + NKG2A bispecific antibody

Phase 1

Phase 1 (Solid tumors)

Phase 1 (Solid tumors)
XB371
Phase 1

Phase 1 (Solid tumors)

Phase 1 (Solid tumors)

Next-generation TF-TOPOi ADC

Next-generation TF-TOPOi ADC

Phase 1

Phase 1 (Solid tumors)

Phase 1 (Solid tumors)
ADU-1805
Phase 1

Option to acquire asset from Sairopa3 pending certain phase 1 results (Solid tumors)

Option to acquire asset from Sairopa3 pending certain phase 1 results (Solid tumors)

SIRPα-targeting mAb

SIRPα-targeting mAb

Phase 1

Option to acquire asset from Sairopa3 pending certain phase 1 results (Solid tumors)

Option to acquire asset from Sairopa3 pending certain phase 1 results (Solid tumors)
XB773
Discovery/Preclinical

DLL3-TOPOi ADC

DLL3-TOPOi ADC

Discovery/Preclinical
SSTR2 Agonist
Discovery/Preclinical

Somatostatin receptor subtype 2 agonist program development candidate

Somatostatin receptor subtype 2 agonist program development candidate

Discovery/Preclinical

1 Merck is sponsoring the study, and Exelixis is supplying the study drugs, zanzalintinib and cabozantinib
2 Merck is sponsoring the study, and Exelixis is supplying the study drug, zanzalintinib
3 Sairopa B.V. (Sairopa) and Exelixis have an exclusive clinical development and option agreement providing Exelixis the right to acquire ADU-1805

  • ADC = antibody-drug conjugate
  • CRC = colorectal cancer
  • DLL3 = delta-like ligand 3
  • IL13Rα2 = interleukin 13 receptor alpha 2
  • IND = investigational new drug application
  • mAb = monoclonal antibody
  • mCRPC = metastatic castration-resistant prostate cancer
  • MMAE = monomethyl auristatin E
  • nccRCC = non-clear cell renal cell carcinoma
  • NET = neuroendocrine tumors
  • NKG2A = natural killer cell receptor group 2A
  • PD-L1 = programmed death-ligand 1
  • PKMYT1 = protein kinase, membrane associated tyrosine/threonine 1
  • RCC = renal cell carcinoma
  • SCCHN = squamous cell carcinoma of head and neck
  • SIRPα = signal regulatory protein alpha
  • SSTR2 = somatostatin receptor 2
  • TF = tissue factor
  • TKI = tyrosine kinase inhibitor
  • TOPOi = topoisomerase inhibitor
  • USP1 = ubiquitin specific peptidase 1
  • VEGFR = vascular endothelial growth factor receptor

Disclaimer: The compounds presented are investigational or are being investigated for uses that have not been approved by the U.S. Food and Drug Administration. The safety and efficacy of these investigational compounds and/or investigational uses have not been established. This information is presented only for purposes of providing a general overview of clinical trials and should not be construed as a recommendation for use of any product for unapproved uses.

You are now leaving the exelixis.com website. This link will take you to a website to which our Privacy Policy does not apply. You are solely responsible for your interactions with that website.

Cancel Continue